(NASDAQ: EVAX) Evaxion A's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.92%.
Evaxion A's earnings in 2025 is -$11,974,000.On average, 4 Wall Street analysts forecast EVAX's earnings for 2025 to be -$692,612,137, with the lowest EVAX earnings forecast at -$928,536,108, and the highest EVAX earnings forecast at -$431,106,050. On average, 4 Wall Street analysts forecast EVAX's earnings for 2026 to be -$607,243,665, with the lowest EVAX earnings forecast at -$857,348,339, and the highest EVAX earnings forecast at -$331,620,038.
In 2027, EVAX is forecast to generate $4,510,032,522 in earnings, with the lowest earnings forecast at $4,333,168,502 and the highest earnings forecast at $4,642,680,538.